Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.
暂无分享，去创建一个
N. Harbeck | O. Gluz | C. Liedtke | S. Kümmel | H. Kreipe | R. Kates | U. Nitz | R. Wuerstlein | H. Forstbauer | C. Schumacher | M. Braun | M. Christgen | B. Aktas | J. Potenberg | A. Kleine-Tebbe | D. Augustin | J. Tio | M. Just | D. Hofmann | Stefan Kraemer